Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards

Critics Pushing for Changes to Kansas’ Prescription Plan

By Pharmaceutical Processing | March 29, 2010

TOPEKA, Kan. (AP) — Claims that the company managing pharmacy benefits for state employees failed to offer the lowest possible prices on many drugs will be the subject of a Legislative committee hearing Monday.

A Washington-based organization representing labor union groups is raising the issue as the state’s contract with CVS Caremark Corp. is on the cusp of expiring at the end of the year. The organization, called Change to Win, also said there have been similar questions about CVS plans in other states, including Illinois and Maryland.

CVS Caremark spokesman Jim Hughes defended the company, saying it saved Kansas millions of dollars and received high marks from plan members for customer service.

“We are confident they will see the real value of our services,” Hughes said.

Hughes said the controversy was tied to a philosophical dispute over the proper approach to union balloting rather than pharmaceutical services.

Casey Cabalquinto, an organizer with Change to Win, said Change to Win’s analysis indicated a person in a CVS Caremark retail discount program would pay less for 260 generic prescription drugs than workers in the Kansas State Employee Health Plan.

The Kansas Health Policy Authority, an agency administering state health programs, hadn’t completed an independent review to examine the organization’s claim, said spokesman Peter Hancock.

“Our concern is making sure we get the best deal we can,” Hancock said.

Democrats and Republicans on the House Government Efficiency and Fiscal Oversight Committee said they supported exploration of complaints about CVS Caremark.

“If what is alleged is true, we’re getting charged a bunch more than we should be,” said Chairman Jim Morrison, R-Colby.

He set up the Monday hearing and a potential second day of debate Tuesday.

 

Related Articles Read More >

FDA logo
FDA prevented 317 drug shortages in 2021
Pfizer-BioNTech vaccine vial
Pfizer, BioNTech moving forward on seeking COVID-19 vaccine EUA for youngest children
FDA logo
FDA curtails use of Janssen COVID-19 vaccine over blood clotting concerns
FDA logo
FDA sends warning letters to CBD and delta-8 THC product vendors

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Pharmaceutical Processing news in a minute?

We Deliver!
Pharmaceutical Processing Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Pharmaceutical Processing World
  • Subscribe to Our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards